167 related articles for article (PubMed ID: 38480731)
1. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice.
Long J; Chen X; He M; Ou S; Zhao Y; Yan Q; Ma M; Chen J; Qin X; Zhou X; Chu J; Han Y
Nat Commun; 2024 Mar; 15(1):2271. PubMed ID: 38480731
[TBL] [Abstract][Full Text] [Related]
2. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
3. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
Jin BY; Campbell TE; Draper LM; Stevanović S; Weissbrich B; Yu Z; Restifo NP; Rosenberg SA; Trimble CL; Hinrichs CS
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669936
[TBL] [Abstract][Full Text] [Related]
4. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract][Full Text] [Related]
5. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
6. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
[TBL] [Abstract][Full Text] [Related]
7. Identification of HPV-E7 specific TCRs for tumor immunotherapy.
Li X; Wang W; Wang J; Jiang M; He J; Tan S
Mol Immunol; 2024 Jul; 171():56-65. PubMed ID: 38795685
[TBL] [Abstract][Full Text] [Related]
8. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
9. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
10. Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P; Köksal H; Maggadottir SM; Winge-Main A; Pollmann S; Menard M; Myhre MR; Mælandsmo GM; Flørenes VA; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Mol Ther; 2021 Mar; 29(3):1199-1213. PubMed ID: 33212301
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
Fujiki F; Morimoto S; Nishida Y; Tanii S; Aoyama N; Inatome M; Inoue K; Katsuhara A; Nakajima H; Nakata J; Nishida S; Tsuboi A; Oka Y; Oji Y; Sogo S; Sugiyama H
Cancer Immunol Immunother; 2023 Jul; 72(7):2347-2356. PubMed ID: 36939853
[TBL] [Abstract][Full Text] [Related]
13. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
14. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
15. Rapid generation of genetically engineered T cells for the treatment of virus-related cancers.
Jiang J; Xia M; Zhang L; Chen X; Zhao Y; Zeng C; Yang H; Liang P; Li G; Li N; Qi H; Wei T; Ren L
Cancer Sci; 2022 Nov; 113(11):3686-3697. PubMed ID: 35950597
[TBL] [Abstract][Full Text] [Related]
16. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
17. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.
Soon CF; Behrendt P; Todt D; Manns MP; Wedemeyer H; Sällberg Chen M; Cornberg M
J Hepatol; 2019 Oct; 71(4):673-684. PubMed ID: 31203151
[TBL] [Abstract][Full Text] [Related]
18. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
[TBL] [Abstract][Full Text] [Related]
19. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
20. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
Dillard P; Casey N; Pollmann S; Vernhoff P; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Oncoimmunology; 2021; 10(1):1936757. PubMed ID: 34235003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]